Efficacy of arsenic trioxide drug-eluting stents in the treatment of coronary heart disease

Abstract

Abstract. The aim of the current study was to evaluate the safety and clinical efficacy of arsenic trioxide drug-eluting (AVI) stents, manufactured in China, for the treatment of coronary heart disease (CHD). Between January and August 2014, 40 patients with CHD admitted to Yongchuan Hospital with implanted AVI stents alone were selected. A one-year clinical follow-up was completed and one year postoperative coronary angiography was reviewed. Major adverse cardiovascular events (MACE), recurrent angina, stent restenosis and stent thrombosis cases were detected. All 40 patients with CHD completed the one-year clinical follow-up, as well as the one-year postoperative coronary angiography. The follow-up results indicated that the MACE rate was 15.0% (6/40), the target lesion revascularization rate was 15.0% (6/40), the angina recurrence rate was 32.5% (13/40), the in-stent restenosis rate was 20.0% (8/40) and the stent thrombosis rate was zero. There were no cases of cardiac death or nonfatal myocardial infarction. The incidence of restenosis was higher following implantation of the AVI stent and the safety and clinical efficacy were worse than expected.

miR-22 Is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation

“…Furthermore, it has been reported that EVI1 protein can be specifically degraded by an anti-cancer drug, arsenic trioxide (ATO)59. Several pre-clinical60, 61 and clinical62, 63 studies suggest that ATO-eluting stent (AES) is a promising alternative to widely used sirolimus’ derivatives-eluting stents. In a rabbit iliac artery injury model, AES significantly suppressed in-stent restenosis by reducing proliferation and inducing apoptosis of VSMCs61.…”

Levels of leachable elements from long-term use of enFlow fluid warmer

“…Studies on arsenic trioxide in coronary stents have provided toxicological information for clinicians. 37 This study identified levels of arsenic in multiple fluids that were well below the FDA's PDE.…”

Arsenic trioxide-eluting electrospun nanofiber-covered self-expandable metallic stent reduces granulation tissue hyperplasia in rabbit trachea

“…Drug-eluting stents are the most promising type of stent for use in the cardiovascular system. An ATOeluting cardiovascular stent received a registration certificate issued by the State Food and Drug Administration (Beijing, China) and has since gained postmarketing clinical data [6]. However, no ATO-eluting stents have been applied in nonvascular lumina until now.…”

“…Vascular drug-eluting stents, fabricated by coating the drug on the bare stent wire for continuous release of the drug to inhibit proliferation, are used to inhibit the proliferation of the vascular intima and have achieved good results [5,6]. Also, a series of biodegradable stent were designed to reduce the hyperplasia of intima [7,8].…”